UK JIA Biologics Register

The UK JIA Biologics Register includes:
- The Biologics for Children with Rheumatic Diseases study (BCRD)
- BSPAR Etanercept Study (BSPAR ETN)

[UK JIA Biologics Register @BCRD_Study]

🚨New research!

📰Published in Lancet Rheumatology @TheLancetRheum

💊Switching from a TNFi originator to a #biosimilar for #JIA❓

✅We found children do just as well as those who remained on the originator (i.e. didn’t switch)

📹Learn more👇or read: https://t.co/zecqD3hooH

[The Lancet Rheumatology @TheLancetRheum]

NEW RESEARCH—@KearsleyFleet and colleagues report outcomes after anti-TNF originator to #biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK @BCRD_Study https://t.co/mCuheFzWbC #JIA @VersusArthritis

[UK JIA Biologics Register @BCRD_Study]

‼️Do not miss this lunchtime...

👩‍🏫Dr @kearsleyfleet presenting:

"Early experience with the JAK inhibitor tofacitinib in JIA from routine clinical practice"

🌟Results from the UK JIA Biologics Register!🌟

⌚️12:40pm
📍Stage 2

#BSR25 #JIA

[UK JIA Biologics Register @BCRD_Study]

⌚️Do not miss our posters this morning in the break, 10:30am...

👩‍🏫P090 - screen 2: "Early experience with the JAK inhibitor tofacitinib"

👨‍🏫P099 - screen 11: "Association between ethnicity and deprivation, with changes in disease activity after 6 months of methotrexate"

#BSR25

[UK JIA Biologics Register @BCRD_Study]

👨‍🏫Do not miss our PhD student, Richard, presenting at BSR 2025 next week!

"The association between ethnicity and deprivation, with changes in disease activity after 6 months of methotrexate in JIA"

🗓️Wed 30th April - 10:30am (morning break)
📊 Screen 11; P099

#BSR25 #JIA

[UK JIA Biologics Register @BCRD_Study]

‼️BSR 2025 next week

👩‍🏫Do not miss Dr @kearsleyfleet presenting:

"Early experience with the JAK inhibitor tofacitinib in JIA"

🗓️Wednesday 30th April
⏲️12:40pm (during lunch)
📍Stage 2

📊 or visit the poster for a chat in the morning break at 10:30am; P090

#BSR25 #JIA

[Lianne Kearsley-Fleet @KearsleyFleet]

📣Have you been diagnosed with childhood-onset arthritis?
❓Are you older than 16 years old?
👉We would really like to hear from you!
📊How do you feel about researchers using your data?
🗣️Your opinion matters!
💻Please complete our survey: https://t.co/9FNNU46sXD
🙌Thank you!!

[UK JIA Biologics Register @BCRD_Study]

The UK JIA Biologics Register (@BCRD_Study and BSPAR Etanercept Study) is part of the NIHR Associate Principal Investigator Scheme.

🔗https://t.co/aSKdMqQ3Sl

If you would like to gain research experience via this programme please get in touch - [email protected]

[UK JIA Biologics Register @BCRD_Study]

Both studies in the UK JIA Biologics Register (the BCRD Study UK CRN ID: 7725 and BSPAR Etanercept Study UK CRN ID: 13553) have joined the NIHR Associate Principal Investigator Scheme! We would love to support you in developing your research career. https://t.co/aSKdMqQ3Sl

[Lianne Kearsley-Fleet @KearsleyFleet]

📊Like analysing large datasets?

👥Want to work in an amazing team?

💊Researching safety of medicines for arthritis?

🏫Where flexible / hybrid working and generous annual leave is possible?

@BSRBR_RA @BCRD_Study @FBMH_UoM @CfE_UoM

🔗Apply now... https://t.co/hQdhhqm2Ee

[Kimme Hyrich @khyrich]

Hey!! Come join our ⁦@BSRBR_RA⁩ study team in Manchester. 2 data science/analyst jobs available!! Details here ⬇️ ⁦@EMEUNET⁩ ⁦@CfE_UoM⁩ ⁦@UoMMskResearch⁩ ⁦@ManchesterBRC⁩ https://t.co/DBcNfsL5Vb

[BSR @RheumatologyUK]

Dr Lianne @KearsleyFleet from @BCRD_Study will discuss the early experience with JAK inhibitors in #JIA in routine clinical practice.

📍 'Advances in our care of children and young people with JIA'

Poster Tour Auditorium 1

⏰ 10:00AM (CEST)

#EULAR2023

[UK JIA Biologics Register @BCRD_Study]

👥 Are you still at #EULAR2023 today?

🚸 Interested in national JAK inhibitor use in JIA?

👩‍🏫Lianne @KearsleyFleet discusses the early experience of #JAKi in #JIA in UK clinical practise (P0S0280)

➡️ Go to Poster Auditorium 2 for the poster tour at 10am (CEST)

[UK JIA Biologics Register @BCRD_Study]

🚨Don’t forget - the post tour starts at 12:00 (CEST)

👩‍🏫 “Outcomes following switching from originator to biosimilar in children and young people with JIA”

📍Poster tour room 1

Details in the #EULAR2023 app 👇👇👇👇

[UK JIA Biologics Register @BCRD_Study]

👥 At #EULAR2023

🚸 Interested in #JIA and #biologics / #biosimilars

➡️ Poster Auditorium 1 for the “What's new in Paediatric RMDs?” Poster Tour at 12pm (CEST)

👩‍🏫 Lianne @KearsleyFleet discusses outcomes following switching from originator to biosimilar product (P0S0132)

[UK JIA Biologics Register @BCRD_Study]

👥 At #EULAR2023

🚸 Interested in #JIA and #biologics / #biosimilars

➡️ Poster Auditorium 1 for the “What's new in Paediatric RMDs?” Poster Tour at 12pm (CEST)

👩‍🏫 Lianne @KearsleyFleet discusses outcomes following switching from originator to biosimilar product (P0S0132)

[JAR Project (now on B___sky) @JARProject]

#JIA research findings from @KearsleyFleet
@BCRD_Study including importance of prompt diagnosis and prompt treatment. #thinkJIA

[BSR @RheumatologyUK]

The UK JIA Biologics Register helps monitor the safety and efficacy of new treatments for #JIA. The @BCRD_Study can now register children and young people with JIA who are newly starting treatment with #Tofacitinib.

✉️ Contact: [email protected] to learn more!

[UK JIA Biologics Register @BCRD_Study]

📣 Interested in doing a #PhD

➡️ Investigating adults with #JIA and the impact on ongoing arthritis, quality of life, and mental health

👥 Join us and @CAPSIE_CAPS at the @CfE_UoM

👩‍🏫 Supervisors: @KearsleyFleet @khyrich @jenny_rheum

📰 Read more: https://t.co/L5hMdti0bM

[UK JIA Biologics Register @BCRD_Study]

👥Next week is #EULAR2023

👩‍🏫Visit our #JIA posters (tours)!

▪️ Friday 1st June:
POS0132 Outcomes following switch from originator to biosimilar
- Auditorium 1 at 12:00 (CEST)

▪️ Saturday 2nd June:
POS0280 Early experience with JAK inhibitors
- Auditorium 2 at 10:00 (CEST)

[ClusterConsortium @CLUSTER_Tweet]

👁️EYE-CHART Need you're help!

✍️Please take 10-15 mins to fill in their survey
⏰Deadline now extended to to Monday 22nd May at 8 am.